Testing the hypothesis that selenium deficiency is a risk factor for clozapine-induced agranulocytosis in rats

Chemical Research in Toxicology

Volumn 21, Issue 4, 2008, Pages 874-878

  Ip, Julia ^a   Uetrecht, Jack P ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; GLUTATHIONE; GLUTATHIONE PEROXIDASE; PROTEIN DISULFIDE ISOMERASE; SELENIUM; SELENOCYSTEINE; THIOREDOXIN REDUCTASE;

AGRANULOCYTOSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD LEVEL; BONE MARROW; DISEASE ASSOCIATION; DRUG EFFECT; DRUG INDUCED DISEASE; DRUG MECHANISM; FEMALE; LEUKOCYTE COUNT; METABOLITE; NEUTROPHIL; NEUTROPHIL COUNT; NONHUMAN; OXIDATION; RAT; RISK FACTOR; SELENIUM DEFICIENCY;

AGRANULOCYTOSIS; ANIMALS; ANTIPSYCHOTIC AGENTS; BONE MARROW; CLOZAPINE; FEMALE; GLUTATHIONE PEROXIDASE; LEUKOCYTE COUNT; LIVER; PROTEINS; RATS; RATS, SPRAGUE-DAWLEY; RISK FACTORS; SELENIUM;

RATTUS;

EID: 43149098302     PISSN: 0893228X     EISSN: None     Source Type: Journal    
DOI: 10.1021/tx7004037     Document Type: Article

References (31)

1. Atkin, K., Kendall, F., Gould, D., Freeman, H., Liberman, J., and O'Sullivan, D. (1996) Neutropenia and agranulocytosis in patients receiving clozapine in the UK and Ireland. Br. J. Psychiatry 169, 483-488.
2. Brown, T. M. (1999) Clozapine, neuroleptic malignant syndrome, and pancerebellar syndrome. Psychosomatics 40, 518-520.
3. Hummer, M., Kurz, M., Kurzthaler, I., Oberbauer, H., Miller, C., and Fleischhacker, W. W. (1997) Hepatotoxicity of clozapine. J. Clin. Psychopharmacol. 17, 314-317.
4. Macfarlane, B., Davies, S., Mannan, K., Sarsam, R., Pariente, D., and Dooley, J. (1997) Fatal acute fulminant liver failure due to clozapine: a case report and review of clozapine-induced hepatotoxicity. Gastroenterology 112, 1707-1709.
5. Killian, J. G., Kerr, K., Lawrence, C., and Celermajer, D. S. (1999) Myocarditis and cardiomyopathy associated with clozapine. Lancet 354, 1841-1845.
6. Fraser, D., and Jibani, M. (2000) An unexpected and serious complication of treatment with the atypical antipsychotic drug clozapine. Clin. Nephrol. 54, 78-80.
7. Southall, K. E. (2000) A case of interstitial nephritis on clozapine. Aust. N. Z. J. Psychiatry 34, 697-698.
8. Liu, Z. C., and Uetrecht, J. P. (1995) Clozapine is oxidized by activated human neutrophils to a reactive nitrenium ion that irreversibly binds to the cells. J. Pharmacol. Exp. Ther. 275, 1476-1483.
9. Linday, L. A., Pippenger, C. E., Howard, A., and Lieberman, J. A. (1995) Free radical scavenging enzyme activity and related trace metals in clozapine-induced agranulocytosis: a pilot study. J. Clin. Psychopharmacol. 15, 353-360.
10. Vaddadi, K. S., Soosai, E., and Vaddadi, G. (2003) Low blood selenium concentrations in schizophrenic patients on clozapine. Br. J. Clin. Pharmacol. 55, 307-309.
11. Johansson, L., Gafvelin, G., and Arner, E. S. (2005) Selenocysteine in proteins-properties and biotechnological use. Biochim. Biophys. Acta 1726, 1-13.
12. Kang, S. I., and Spears, C. P. (1990) Structure-activity studies on organoselenium alkylating agents. J. Pharm. Sci. 79, 57-62.
13. Rayman, M. P. (2000) The importance of selenium to human health. Lancet 356, 233-241.
14. Brown, K. M., and Arthur, J. R. (2001) Selenium, selenoproteins and human health: a review. Public Health Nutr. 4, 593-599.
15. Papp, L. V., Lu, J., Holmgren, A., and Khanna, K. K. (2007) From selenium to selenoproteins: synthesis, identity, and their role in human health. Antioxid. Redox Signaling 9, 775-806.
16. Holben, D. H., and Smith, A. M. (1999) The diverse role of selenium within selenoproteins: a review. J. Am. Diet Assoc. 99, 836-843.
17. Moghadaszadeh, B., and Beggs, A. H. (2006) Selenoproteins and their impact on human health through diverse physiological pathways. Physiology (Bethesda) 21, 307-315.
18. Schomburg, L., Schweizer, U., and Kohrle, J. (2004) Selenium and selenoproteins in mammals: extraordinary, essential, enigmatic. Cell. Mol. Life Sci. 61, 1988-1995.
19. Hoffmann, P. R. (2007) Mechanisms by which selenium influences immune responses. Arch. Immunol. Ther. Exp. (Warsz).
20. Arthur, J. R., McKenzie, R. C., and Beckett, G. J. (2003) Selenium in the immune system. J. Nutr. 133, 1457S-1459S.
21. Hill, K. E., Burk, R. F., and Lane, J. M. (1987) Effect of selenium depletion and repletion on plasma glutathione and glutathione-dependent enzymes in the rat. J. Nutr. 117, 99-104.
22. Matsuda, A., Kimura, M., and Itokawa, Y. (1998) Influence of selenium deficiency on vital functions in rats. Biol. Trace Elem. Res. 61, 287-301.
23. Ullrey, D. E. (1987) Biochemical and physiological indicators of selenium status in animals. J. Anim. Sci. 65, 1712-1726.
24. Gardner, I., Leeder, J. S., Chin, T., Zahid, N., and Uetrecht, J. P. (1998) A comparison of the covalent binding of clozapine and olanzapine to human neutrophils in vitro and in vivo. Mol. Pharmacol. 53, 999-1008.
25. Leonard, R., and Ruben, Z. (1986) Hematology reference values for peripheral blood of laboratory rats. Lab. Anim. Sci. 36, 277-281.
26. Qiu, Y., Benet, L. Z., and Burlingame, A. L. (1998) Identification of the hepatic protein targets of reactive metabolites of acetaminophen in vivo in mice using two-dimensional gel electrophoresis and mass spectrometry. J. Biol. Chem. 273, 17940-17953.
27. Pumford, N. R., Martin, B. M., and Hinson, J. A. (1992) A metabolite of acetaminophen covalently binds to the 56 kDa selenium binding protein. Biochem. Biophys. Res. Commun. 182, 1348-1355.
28. Bartolone, J. B., Birge, R. B., Bulera, S. J., Bruno, M. K., Nishanian, E. V., Cohen, S. D., and Khairallah, E. A. (1992) Purification, antibody production, and partial amino acid sequence of the 58-kDa acetaminophen-binding liver proteins. Toxicol. Appl. Pharmacol. 113, 19-29.
29. Sirota, P., Gavrieli, R., and Wolach, B. (2003) Overproduction of neutrophil radical oxygen species correlates with negative symptoms in schizophrenic patients: parallel studies on neutrophil chemotaxis, superoxide production and bactericidal activity. Psychiatry Res. 121, 123-132.
30. Gysin, R.,Kraftsik, R.,Sandell, J.,Bovet, P.,Chappuis, C.,Conus, P.,Deppen, P.,Preisig, M.,Ruiz, V.,Steullet, P.,Tosic, M.,Werge, T.,Cuenod, M.,and Do, K. Q. (2007) Impaired glutathione synthesis in schizophrenia: Convergent genetic and functional evidence. Proc. Natl. Acad. Sci. U.S.A.
31. Mahadik, S. P., Evans, D., and Lal, H. (2001) Oxidative stress and role of antioxidant and omega-3 essential fatty acid supplementation in schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 25, 463-493.